Harnessing RNAi nanomedicine for precision therapy

Area of Science:

• Biotechnology
• Molecular Biology
• Pharmacology

Background:

• RNA interference (RNAi) presents a promising therapeutic strategy for precision medicine.
• Current RNAi therapies face challenges in targeted delivery of payloads like small interfering RNAs (siRNAs), microRNAs (miRs), and anti-miRs (antagomirs).
• Overcoming systemic, local, and cellular barriers is crucial for effective RNAi drug delivery.

Purpose of the Study:

• To review recent advancements in RNA interference (RNAi) drug delivery.
• To highlight strategies for achieving passive tissue targeting and active cellular targeting of RNAi payloads.
• To discuss the development of nano-sized carriers for overcoming delivery barriers.

Main Methods:

• Review of recent progress in RNAi therapeutic development.
• Analysis of passive targeting strategies for systemic delivery.
• Examination of active targeting approaches for cellular specificity.

Main Results:

• Significant progress has been made in developing nanocarriers for RNAi delivery.
• Strategies for passive tissue targeting and active cellular targeting are advancing.
• Initial clinical trials show positive results, indicating therapeutic potential.

Conclusions:

• RNAi-based therapeutics hold immense potential for revolutionizing precision medicine.
• Nanocarrier technology is key to overcoming targeted delivery challenges in RNAi therapy.
• Continued research into targeting strategies is essential for realizing the full clinical benefit of RNAi.